epirubicin

P2, N=216, Not yet recruiting, Henan Cancer Hospital

Ten-year outcomes for TC and EC-T were similar and excellent; six cycles of TC is an effective option in HER2-negative eBC with pN0 or pN1 and intermediate-to-high-risk disease, according to gene expression analysis.

P2, N=302, Not yet recruiting, First Affiliated Hospital of Wenzhou Medical University

P3, N=1560, Active, not recruiting, Fudan University | Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Jul 2027 | Trial primary completion date: Jul 2021 --> Jul 2026

P3, N=550, Completed, Italian Sarcoma Group | Active, not recruiting --> Completed

Pre-treatment RTL was not prognostic, although IL6/IL8 were negative prognostic factors in advanced disease. Levels of these were lower in patients with localised disease, suggesting an association with disease progression. Further analysis of systemic inflammatory status in gastro-oesophageal adenocarcinoma may be promising for development of future predictive biomarker signatures.

FGD3 is a key mediator of chemotherapy-induced plasma membrane rupture and lytic cell death. It is also a useful biomarker for identifying breast cancer patients most likely to benefit from lytic cell death-inducing immunogenic anticancer therapies.

Among them, Epirubicin, Doxorubicin, and Daunorubicin; all anthracycline chemotherapy agents; are known to inhibit cancer progression by slowing or halting cell growth. Molecular dynamics simulations further validated the QSAR screening results, confirming that Epirubicin forms the most stable and tightly bound complex with PI3Kγ, with ΔGbind values of -3.81 kcal/mol for PI3Kγ-M192 and -4.47 kcal/mol for PI3Kγ-Epirubicin. These findings indicate that the QSAR model could function as a targeted screening tool, facilitating the identification of drugs with strong affinity for the PI3Kγ receptor, and ultimately improving the hit rate compared to random screening approaches.

The impact of HER2 expression on the recurrence-free survival (RFS) of patients with intravesical anthracycline (epirubicin or pirarubicin) instillation after transurethral resection of bladder tumor (TURBT) was evaluated. In the patients treated with intravesical anthracycline instillation, HER2 high-expression was associated with a shorter RFS (P<0.001). HER2 high-expression seems to be not only associated with worse clinicopathological features of NMIBC but also a poor RFS in NMIBC patients treated with anthracycline instillation after TURBT.

Treatment consisted of neoadjuvant chemotherapy (epirubicin + carboplatin + trastuzumab + pertuzumab), a modified radical mastectomy with latissimus dorsi flap reconstruction and a thoracoscopic lung wedge resection. The therapeutic approach resulted in partial remission of the breast cancer prior to surgery and a stable disease status in the lung, with no recurrence at the 1-year follow-up. This case underscores the importance of comprehensive, integrative strategies and long-term follow-up for managing rare, complex cancer cases.

P2, N=64, Not yet recruiting, Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital

Notably, aTIM-3 showed stronger anti-tumor effects than aPD-1 when combined with EPI in several GBM models, largely through enhanced macrophage polarization and phagocytic activity. Overall, this targeted system, which leverages chemotherapy-induced ICD to improve TIM-3 anti-tumor efficacy, holds substantial promise as a therapeutic strategy for GBM.